Back to Search
Start Over
TLR2/4 promotes PGE 2 production to increase tissue damage in Escherichia coli-infected bovine endometrial explants via MyD88/p38 MAPK pathway.
- Source :
-
Theriogenology [Theriogenology] 2020 Aug; Vol. 152, pp. 129-138. Date of Electronic Publication: 2020 Apr 07. - Publication Year :
- 2020
-
Abstract
- Prostaglandin E2 (PGE <subscript>2</subscript> ), a lipid mediator, is released by several cell types including endometrial cells and plays a central role in bacterial infection of the endometrium during inflammation. PGE <subscript>2</subscript> production accumulated in Escherichia coli (E. coli) -infected bovine endometrial tissue, which increased E. coli-infected endometrial tissue damage. However, the mechanisms of PGE <subscript>2</subscript> accumulation in the E. coli-infected endometrium during inflammation-associated endometrial tissue damage remain unclear. This study was conducted to investigate the role of Toll-like receptors (TLRs) 2 and 4 in increased PGE <subscript>2</subscript> production in E. coli-infected endometrial tissue. E. coli and TLR2/4 agonists significantly induced cyclooxygenase-2 and microsomal prostaglandin E synthase-1 expression and PGE <subscript>2</subscript> synthesis detected by RT-PCR, Western blot, and ELISA in the endometrial tissue. The expression and synthesis were dramatically decreased by TLR4, myeloid differentiation factor88 (MyD88), and p38 mitogen-activated protein kinase (MAPK) inhibitors in E. coli-infected endometrial tissue. These inhibitors also significantly decreased proinflammatory factor (interleukin-6 and tumor necrosis factor-α) and damage-associated molecular pattern (high mobility group box-1 and hyaluronan-binding protein-1) release and tissue damage measured by double-label immunofluorescence in E. coli-infected endometrial explants. Our work provides in vitro evidence that TLR2/4-MyD88/p38 MAPK promotes PGE <subscript>2</subscript> synthesis and E. coli-infected endometrial tissue damage, which may be useful for improving PGE <subscript>2</subscript> -based therapies for endometritis.<br />Competing Interests: Declaration of competing interest The authors declare that they have no competing interests.<br /> (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Subjects :
- Animals
Cattle
Dinoprostone genetics
Dinoprostone metabolism
Escherichia coli classification
Female
Gene Expression
Gene Expression Regulation drug effects
Heterocyclic Compounds, 2-Ring administration & dosage
Heterocyclic Compounds, 2-Ring pharmacology
Imidazoles administration & dosage
Imidazoles pharmacology
Lactones administration & dosage
Lactones pharmacology
Lipopeptides administration & dosage
Lipopeptides pharmacology
Lipopolysaccharides administration & dosage
Lipopolysaccharides pharmacology
Myeloid Differentiation Factor 88 antagonists & inhibitors
Myeloid Differentiation Factor 88 genetics
Pyridines administration & dosage
Pyridines pharmacology
Sesquiterpenes administration & dosage
Sesquiterpenes pharmacology
Spiro Compounds administration & dosage
Spiro Compounds pharmacology
Sulfonamides administration & dosage
Sulfonamides pharmacology
Tissue Culture Techniques
Toll-Like Receptor 2 agonists
Toll-Like Receptor 2 antagonists & inhibitors
Toll-Like Receptor 4 agonists
Toll-Like Receptor 4 antagonists & inhibitors
p38 Mitogen-Activated Protein Kinases antagonists & inhibitors
p38 Mitogen-Activated Protein Kinases genetics
Endometrium microbiology
Escherichia coli metabolism
Myeloid Differentiation Factor 88 metabolism
Toll-Like Receptor 2 metabolism
Toll-Like Receptor 4 metabolism
p38 Mitogen-Activated Protein Kinases metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1879-3231
- Volume :
- 152
- Database :
- MEDLINE
- Journal :
- Theriogenology
- Publication Type :
- Academic Journal
- Accession number :
- 32408026
- Full Text :
- https://doi.org/10.1016/j.theriogenology.2020.04.004